Senate Files

Bills

H.R. 3269 119th Congress

ETHIC Act

Latest action, May 8, 2025: Referred to the House Committee on the Judiciary.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

9 cosponsors

Sponsored by Rep. Arrington, Jodey C. [R-TX-19] (Republican). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
6 D · 3 R

Referred to: House: Judiciary Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

25 clientsQ1 2025Q3 2026

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

ASSOCIATION FOR ACCESSIBLE MEDICINES
6 reports
ASSOCIATION OF ACCESSIBLE MEDICINES
MEHLMAN CONSULTING, INC.
6 reports
GSK (FKA GLAXOSMITHKLINE INC.)
6 reports
NOVARTIS
6 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
6 reports
THE CAMPAIGN FOR SUSTAINABLE RX PRICING
MEHLMAN CONSULTING, INC.
6 reports
COUNCIL FOR INNOVATION PROMOTION (C4IP)
5 reports
FRESENIUS KABI
S-3 GROUP
5 reports
FRESENIUS KABI USA LLC
5 reports
JOHNSON & JOHNSON SERVICES INC
5 reports
AMGEN INC
4 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
WHITMER & WORRALL, LLC
4 reports
PUBLIC CITIZEN
4 reports
AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)
3 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
3 reports
All 25 of 32 clients
ClientLobbying firmReportsReports totalingFromToSenate
ASSOCIATION FOR ACCESSIBLE MEDICINES6$4.9MQ4 2025Q3 2026yes
ASSOCIATION OF ACCESSIBLE MEDICINESMEHLMAN CONSULTING, INC.6$360KQ4 2025Q3 2026yes
GSK (FKA GLAXOSMITHKLINE INC.)6$8.1MQ4 2025Q3 2026yes
NOVARTIS6$9.8MQ4 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA6$51.6MQ4 2025Q3 2026yes
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGMEHLMAN CONSULTING, INC.6$540KQ4 2025Q3 2026yes
COUNCIL FOR INNOVATION PROMOTION (C4IP)5$450KQ4 2025Q3 2026yes
FRESENIUS KABIS-3 GROUP5$0Q4 2025Q3 2026yes
FRESENIUS KABI USA LLC5$3.1MQ4 2025Q3 2026yes
JOHNSON & JOHNSON SERVICES INC5$11.2MQ4 2025Q3 2026yes
AMGEN INC4$11.7MQ4 2025Q3 2026yes
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)WHITMER & WORRALL, LLC4$200KQ4 2025Q2 2026yes
PUBLIC CITIZEN4$406KQ4 2025Q3 2026yes
AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)3$30KQ1 2026Q3 2026yes
BIOTECHNOLOGY INNOVATION ORGANIZATION3$6.5MQ1 2026Q3 2026yes
CONSERVATIVES FOR PROPERTY RIGHTSELITE STRATEGIC SERVICES3$148KQ4 2025Q1 2026yes
GENENTECH, INC.YC CONSULTING, LLC3$0Q1 2026Q3 2026—
KAISER FOUNDATION HEALTH PLAN INC3$4.0MQ1 2026Q3 2026yes
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION3$9.6MQ2 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAYC CONSULTING, LLC3$0Q1 2026Q3 2026—
AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS2$510KQ2 2026Q3 2026yes
BAYER CORPORATION (CONSOLIDATED REPORT)2$3.5MQ2 2026Q3 2026yes
CHAMBER OF COMMERCE OF THE U.S.A.2$33.4MQ2 2026Q3 2026yes
NFIB (NATIONAL FEDERATION OF INDEPENDENT BUSINESS)2$3.6MQ2 2026Q3 2026yes
T1INTERNATIONAL USA2$0Q1 2026Q3 2026yes